1.28
-0.03(-2.29%)
Currency In USD
| Previous Close | 1.31 |
| Open | 1.32 |
| Day High | 1.35 |
| Day Low | 1.27 |
| 52-Week High | 5.2 |
| 52-Week Low | 1.26 |
| Volume | 646,637 |
| Average Volume | 903,738 |
| Market Cap | 136.54M |
| PE | -2.98 |
| EPS | -0.43 |
| Moving Average 50 Days | 1.56 |
| Moving Average 200 Days | 1.9 |
| Change | -0.03 |
If you invested $1000 in MaxCyte, Inc. (MXCT) since IPO date, it would be worth $75.29 as of January 14, 2026 at a share price of $1.28. Whereas If you bought $1000 worth of MaxCyte, Inc. (MXCT) shares 3 years ago, it would be worth $225.75 as of January 14, 2026 at a share price of $1.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire Inc.
Jan 12, 2026 1:05 PM GMT
ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gen
MaxCyte Announces Planned CFO Transition in 2026
GlobeNewswire Inc.
Nov 12, 2025 9:08 PM GMT
Company initiates search for successorROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and co
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
GlobeNewswire Inc.
Oct 08, 2025 12:05 PM GMT
ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cel